ID   ANBL-6
AC   CVCL_5425
SY   ANBL6
DR   ArrayExpress; E-TABM-1088
DR   cancercelllines; CVCL_5425
DR   Cosmic; 720790
DR   Cosmic; 1170891
DR   Cosmic; 2081377
DR   Cosmic; 2367285
DR   IARC_TP53; 28510
DR   Wikidata; Q54749908
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8221668;
RX   PubMed=8943038;
RX   PubMed=10583232;
RX   PubMed=10936422;
RX   PubMed=11154231;
RX   PubMed=11157491;
RX   PubMed=16956823;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=19344406;
RX   PubMed=21173094;
RX   PubMed=23992230;
RX   PubMed=24013424;
RX   PubMed=25015330;
RX   PubMed=25688540;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=ANBL-6
CC   Population: Caucasian.
CC   Characteristics: Produces Ig lambda.
CC   Characteristics: IL6 dependent.
CC   HLA typing: A*01,03; B*51,52; C*12:02,12:03 (Direct_author_submission).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Unspecified (PubMed=21173094).
CC   Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Tyr425Thrfs*36 (c.1272delC); Zygosity=Homozygous (PubMed=17692805).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M523 ! ANBM-6
SX   Female
AG   67Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=8221668;
RA   Jelinek D.F., Ahmann G.J., Greipp P.R., Jalal S.M., Westendorf J.J.,
RA   Katzmann J.A., Kyle R.A., Lust J.A.;
RT   "Coexistence of aneuploid subclones within a myeloma cell line that
RT   exhibits clonal immunoglobulin gene rearrangement: clinical
RT   implications.";
RL   Cancer Res. 53:5320-5327(1993).
//
RX   PubMed=8943038; DOI=10.1073/pnas.93.24.13931;
RA   Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L.,
RA   Kuehl W.M.;
RT   "Promiscuous translocations into immunoglobulin heavy chain switch
RT   regions in multiple myeloma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).
//
RX   PubMed=10583232; DOI=10.1046/j.1365-2141.1999.01705.x;
RA   Puthier D., Derenne S., Barille S., Moreau P., Harousseau J.-L.,
RA   Bataille R., Amiot M.;
RT   "Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.";
RL   Br. J. Haematol. 107:392-395(1999).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11154231; DOI=10.1182/blood.V97.2.516;
RA   Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A.,
RA   Sundan A.;
RT   "Bone morphogenetic protein-4 inhibits proliferation and induces
RT   apoptosis of multiple myeloma cells.";
RL   Blood 97:516-522(2001).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A.,
RA   Kuehl W.M., Bergsagel P.L.;
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=16956823;
RA   Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L.,
RA   Moreau P., Amiot M., Pellat-Deceunynck C.;
RT   "The phenotype of normal, reactive and malignant plasma cells.
RT   Identification of 'many and multiple myelomas' and of new targets for
RT   myeloma therapy.";
RL   Haematologica 91:1234-1240(2006).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=19344406; DOI=10.1111/j.1365-2141.2009.07647.x;
RA   Voorhees P.M., Chen Q., Small G.W., Kuhn D.J., Hunsucker S.A.,
RA   Nemeth J.A., Orlowski R.Z.;
RT   "Targeted inhibition of interleukin-6 with CNTO 328 sensitizes
RT   pre-clinical models of multiple myeloma to dexamethasone-mediated cell
RT   death.";
RL   Br. J. Haematol. 145:481-490(2009).
//
RX   PubMed=21173094; DOI=10.3324/haematol.2010.033456;
RA   Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D.,
RA   Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "A high-risk signature for patients with multiple myeloma established
RT   from the molecular classification of human myeloma cell lines.";
RL   Haematologica 96:574-582(2011).
//
RX   PubMed=23992230; DOI=10.1111/ejh.12192;
RA   Greenberg A.J., Walters D.K., Kumar S.K., Rajkumar S.V., Jelinek D.F.;
RT   "Responsiveness of cytogenetically discrete human myeloma cell lines
RT   to lenalidomide: lack of correlation with cereblon and interferon
RT   regulatory factor 4 expression levels.";
RL   Eur. J. Haematol. 91:504-513(2013).
//
RX   PubMed=24013424; DOI=10.4161/cc.26193;
RA   Walters D.K., Arendt B.K., Jelinek D.F.;
RT   "CD147 regulates the expression of MCT1 and lactate export in multiple
RT   myeloma cells.";
RL   Cell Cycle 12:3175-3183(2013).
//
RX   PubMed=25015330; DOI=10.18632/oncotarget.2159;
RA   Arendt B.K., Walters D.K., Wu X., Tschumper R.C., Jelinek D.F.;
RT   "Multiple myeloma cell-derived microvesicles are enriched in CD147
RT   expression and enhance tumor cell proliferation.";
RL   Oncotarget 5:5686-5699(2014).
//
RX   PubMed=25688540; DOI=10.1002/cyto.a.22643;
RA   Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P.,
RA   Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A.,
RA   Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.;
RT   "A simple flow cytometry-based barcode for routine authentication of
RT   multiple myeloma and mantle cell lymphoma cell lines.";
RL   Cytometry A 87:285-288(2015).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//